Mortalitya | ||
---|---|---|
Hazard ratio (95 % CI) | P-value* | |
Race | ||
White vs. non-white | 0.70 (0.39–1.26) | 0.231 |
Lung-function decline group | ||
Marginal decline vs. stable | 2.38 (1.04–5.45) | 0.036* |
Significant decline vs. stable | 4.42 (2.01–9.71) | <0.001* |
BMI | ||
25–30 vs. < 25 | 0.53 (0.29–0.97) | 0.038* |
≥30 vs. < 25 | 0.38 (0.18–0.80) | 0.012* |
Comorbidities | ||
Cardiac disorder vs. no cardiac disorder | 1.63 (0.94–2.82) | 0.080 |
Pulmonary hypertension vs. no pulmonary hypertension | 2.53 (1.33–4.80) | 0.005* |
Emphysema vs. no emphysema | 1.49 (0.67–3.35) | 0.328 |
Gastroesophageal reflux disease vs. no gastroesophageal reflux disease | 1.10 (0.64–1.92) | 0.725 |
Smoking status | ||
History of smoking vs. no history of smoking | 1.08 (0.64–1.83) | 0.773 |
Suspected AEx in the concurrent period | ||
Yes vs. no | 2.59 (1.49–4.53) | <0.001* |
Use of prednisone and azathioprine in the concurrent period | ||
Both vs. neither | 2.48 (1.19–5.19) | 0.016* |
Prednisone only vs. neither | 1.41 (0.66–3.01) | 0.376 |
Azathioprine only vs. neither | 1.11 (0.18–7.01) | 0.909 |
Symptoms at initial IPF diagnosis | ||
Dyspnea vs. no dyspnea | 1.29 (0.48–3.48) | 0.609 |
Weight loss vs. no weight loss | 1.95 (1.02–3.73) | 0.044* |
Physician's main practice setting | ||
Academic vs. non-academic | 0.95 (0.51–1.77) | 0.876 |
GAP index (per unit increase)b | 1.19 (0.98–1.44) | 0.080 |